home / stock / evax / evax quote
Last: | $4.18 |
---|---|
Change Percent: | -3.16% |
Open: | $4.25 |
Close: | $4.18 |
High: | $4.33 |
Low: | $4.02 |
Volume: | 25,104 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.18 | $4.25 | $4.18 | $4.33 | $4.02 | 25,104 | 04-26-2024 |
$4.12 | $4.11 | $4.12 | $4.13 | $3.85 | 7,185 | 04-25-2024 |
$4.13 | $4.18 | $4.13 | $4.18 | $4.05 | 10,156 | 04-24-2024 |
$4.14 | $4.28 | $4.14 | $4.28 | $3.99 | 25,022 | 04-23-2024 |
$4.19 | $4.36 | $4.19 | $4.36 | $4.19 | 9,891 | 04-22-2024 |
$4.31 | $4.24 | $4.31 | $4.4095 | $4.1701 | 30,943 | 04-19-2024 |
$4.22 | $4.11 | $4.22 | $4.2482 | $4.11 | 35,375 | 04-18-2024 |
$4.11 | $4.1 | $4.11 | $4.15 | $3.93 | 29,921 | 04-17-2024 |
$4.04 | $4 | $4.04 | $4.11 | $3.9 | 25,139 | 04-16-2024 |
$4.1 | $3.98 | $4.1 | $4.19 | $3.8574 | 44,816 | 04-15-2024 |
$4.1 | $3.8 | $4.1 | $4.13 | $3.8 | 30,866 | 04-12-2024 |
$3.89 | $4 | $3.89 | $4 | $3.52 | 34,247 | 04-11-2024 |
$3.99 | $4.17 | $3.99 | $4.17 | $3.84 | 38,481 | 04-10-2024 |
$3.96 | $4 | $3.96 | $4.1099 | $3.85 | 36,207 | 04-09-2024 |
$4.09 | $3.7 | $4.09 | $4.11 | $3.7 | 88,525 | 04-08-2024 |
$3.69 | $3.65 | $3.69 | $3.85 | $3.59 | 45,188 | 04-05-2024 |
$3.65 | $3.71 | $3.65 | $3.8458 | $3.65 | 41,978 | 04-04-2024 |
$3.6 | $3.88 | $3.6 | $4.199 | $3.48 | 162,486 | 04-03-2024 |
$3.88 | $3.4 | $3.88 | $3.9 | $3.15 | 310,637 | 04-02-2024 |
$3.23 | $3.2 | $3.23 | $3.4464 | $3.08 | 23,332 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promisi...
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completi...